Unicorn Nest news
SmartLabs Announces $250 Million Series B and Update of Proprietary Laboratory OS
– SmartLabs, a Boston-based Laboratory-as-a-Service (LaaS) leader, announced the raise of a $250m Series B financing.
– The funding round was led by ArrowMark Partners. New investment partners include Winslow Capital Management and Onex Falcon, joined by existing investors Conversion Venture Capital (CVC2) and Breed’s Hill Capital.
– The funding will fuel the company’s accelerated growth, with a plan to scale operations to 2m sq ft within five years.
– In addition, SmartLabs announced the launch of the fourth version of its proprietary laboratory operations system (SmartLabs OS) which was first pioneered and introduced in 2016.
Unicorn Nest news
Tvardi Therapeutics Raises $74M in Series B Financing
– Tvardi Therapeutics, Inc. from Houston, Texas is a clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors.
– The company closed a $74m Series B funding.
– The round was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital with participation from existing investors including Sporos Bioventures.
– The new investment will be aimed at advancing its product candidates through multiple clinical data readouts in mid-stage trials for cancer and fibrosis.
Unicorn Nest news
Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19
– Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the completion of a $336m Series C financing led by RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor.
– Existing investors Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab and Omega Funds also participated in the financing.
Unicorn Nest news
Dataminr Closes $475M Financing at $4.1 Billion Valuation
– Dataminr is a real-time information discovery company based in NYC.
– The company closed $475m round of financing at a $4.1b valuation.
– The round was led by Eldridge, Valor Equity Partners, MSD Capital, Reinvent Capital, ArrowMark Partners, IVP, Eden Global, investment funds managed by Morgan Stanley Tactical Value and Lurra Capital.
– The new investment will be used to accelerate the company’s growth.
Unicorn Nest news
Amunix Raises $117M in Series B Financing
– Amunix Pharmaceuticals from South San Francisco develops masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers.
– Series B $117m round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management and existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital, and Polaris Partners.
Unicorn Nest news
Amunix Pharmaceuticals Receives $117M
– Amunix Pharmaceuticals, a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, has raised $117m Series B financing.
– The funding round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management.
